Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
February 4th 2024Subsequent therapies in patients with metastatic hormone-sensitive prostate cancer who were censored from primary overall survival follow-up from the ARASENS trial, according to a post hoc sensitivity analysis, confirmed the overall survival benefit derived from darolutamide plus androgen deprivation therapy and docetaxel.
Abiraterone Plus Prednisone, Apalutamide Improves Prostate Cancer Outcomes Without Impacting HRQoL
January 31st 2024After radical prostatectomy, patients with prostate cancer treated with abiraterone acetate plus prednisone and apalutamide had improved outcomes without a significant impact on their health-related quality of life.
Nivolumab Plus Ipilimumab Significantly Improves PFS in mCRC
January 30th 2024First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.
Sacituzumab Govitecan Did Not Provide OS Benefit in Pretreated NSCLC
January 29th 2024Researchers determined that the phase 3 EVOKE-01 trial failed to meet its primary end point of significantly improved OS with sacituzumab govitecan in patients with pretreated non-small cell lung cancer compared with docetaxel.
Darolutamide With ADT Before Surgery May Be Safe, Effective in Prostate Cancer
January 28th 2024Researchers did not observe any grade 3 or 4 adverse events with darolutamide with androgen deprivation therapy for 6 months followed by radical prostatectomy in patients with locally advanced prostate cancer.
High-Dose Radiation, Long-Term ADT May Be Standard for High-Risk Prostate Cancer
January 26th 2024Patients with high-risk prostate cancer treated with a higher dose of radiation therapy and long-term androgen deprivation therapy improved progression-free, cancer-specific, and overall survival compared with the standard dose of radiation.
Firstline Olaparib-Based Treatment Improves PFS, Responses in mCRPC
January 26th 2024Frontline olaparib plus abiraterone/prednisone improved progression-free survival and responses in patients with metastatic castration-resistant prostate cancer compared with each of the components of the therapy alone.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Standard-of-Care HRRm Testing Underutilized in Patients With mCRPC
January 25th 2024Despite germline and somatic testing being the standard of care for patients with metastatic castration-resistant prostate cancer, rates of its real-world use shows that it may be underutilized, which may negatively impact therapeutic offerings.
Darolutamide Plus ADT May Lower Hospitalization Rates, Slightly Prolong Stays in mHSPC
January 25th 2024Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”